Skip to Content

Medical Devices & Diagnostics Panel

“Growth and Innovation in an Increasingly Challenging Regulatory & Competitive Environment”

  • Moderator: David Martin, Principle, Deloitte Consulting
  • Nick Conti PhD, Vice President Business Development, Quest Diagnostics
  • Robert Friedman, Managing Director, Easton Associates
  • Michael (Mike) Harsh, Vice President and Chief Technology Officer, GE Healthcare
  • Kendall O’Brien, Vice President, Group Finance Medical Device and Diagnostics, Group Operating Committee, Johnson & Johnson.

ISSUES

  • Examples of novel medical technologies being developed to improve patient care and/or reduce healthcare costs.
  • Impact of regulatory changes and increased emphasis on safety (e.g., in 510(k) submissions) on new product development.
  • Role of emerging markets in company strategy, and challenges companies and investors face in generating acceptable returns.
  • Opportunities and conflicts of partnering diagnostics and devices with therapeutics.
  • How business strategies are incorporating the increasing need to collaborate with providers and payors to drive technology and business decisions.
  • Impact of economic downturn on sales of medical devices and related products.


David Martin
Principal
Deloitte Consulting LLP

David is a Principal in Deloitte's strategy practice focused on growth and innovation in the Life Sciences sector. He is Deloitte's US market offering leader for corporate and business unit strategy.

David has 15 years of experience formulating and executing strategy projects for global pharmaceutical and medical device companies. He has led the creation of multiple product and market strategies for global life sciences firms to leverage the breadth of portfolios and channels across multiple geographies. To identify growth opportunities for his clients, David has focused on the evolution of global healthcare systems, and unmet needs for clinicians, payers, providers and patients in many countries. He has covered numerous diseases, treatment options and payment models, seeking to make healthcare accessible and affordable across various modalities of treatment.

nick Conti PhD
Vice President Business Development
Quest Diagnostics

Nick Conti is Vice President, Business Development. He is responsible for licensing and technology transactions as well as the development and management of strategic alliances for the company. He has led licensing efforts which have resulted in licensing dozens of new technologies that have been developed into new clinical assays.

Dr. Conti joined Quest Diagnostics in 2006. Prior to joining the company, he was Vice President, Business Development for Becton Dickinson. Dr. Conti started his career at Union Carbide as a scientist engaged in catalysis research for their plastics division.

Dr. Conti is a graduate of Notre Dame with a bachelor’s degree in chemistry. He received his Ph.D. in chemistry from the University of Florida and his M.B.A. from the Wharton School. Additionally, Dr. Conti is an Overseas Fellow of the Royal Society of Medicine.

Robert Friedman
Managing Director
Easton Associates

Robert Friedman, Managing Director, holds an M.B.A. from the Johnson School of Management, Cornell University, with a focus on finance and marketing. Additionally, Mr. Friedman holds an M.S. in biochemistry from Columbia University and a B.A. in biology from Yeshiva University. Mr. Friedman co-founded Easton Associates following a nine-year period in management consulting at The Wilkerson Group. Prior to his career in management consulting, Mr. Friedman worked on Wall Street where he was a Senior Equities Analyst in Biotechnology.

His recent consulting engagements have included:

  • For a large medical device company, performed a product, market and technical due diligence on a potential acquisition target in the drug delivery arena. Advised the client on how best to profit from the target's product pipeline (internal development and marketing vs. out-licensing).
  • Helped a leading medical products company devise strategies for accelerating market development for its products and led the management team through a process to identify new business growth platforms.
  • For a major ophthalmic products company, evaluated key current and future market forces impacting on its business, and developed a strategy to defend its near-term franchise while positioning the company to ultimately benefit from these changes.
  • For a major consumer products and health care concern, developed a strategy to build a sustainable and profitable business in pharmaceuticals. Assessed alternative options, including outright acquisition, joint venture and co-marketing, and recommended potential strategic partners.
  • For a leading biotechnology company, assessed options for building an immunology/inflammatory disease franchise, with particular focus on autoimmune diseases, such as diabetes, rheumatoid arthritis and lupus.
Michael (Mike) Harsh
Vice President and Chief Technology Officer
GE Healthcare

Michael J. “Mike” Harsh is Vice President and Chief Technology Officer for GE Healthcare, a $17 billion division of General Electric that helps its customers to deliver better care to more people around the world at a lower cost. GE Healthcare consists of diverse businesses including medical imaging and information technologies, medical diagnostics, patient monitoring systems, technologies facilitating drug discovery, biopharmaceutical manufacturing technologies, and performance improvement and performance solutions services.

Mike leads the global Science and Technology Organization for GE Healthcare, focusing its research and development teams on creating and sustaining innovative diagnostics, healthcare IT, and life sciences product offerings that reduce healthcare costs, improve healthcare quality, and increase patient access to healthcare globally.

Mike began his career at GE in 1979 as an electrical design engineer in nuclear imaging, and subsequently held numerous design and engineering management positions with X-ray, Ultrasound, Magnetic Resonance Imaging (MRI), Patient Monitoring, and Information Technologies.

Subsequently, Mike was named Global Technology Leader - Imaging Technologies Lab at the GE Global Research Center, where he led the research for imaging technologies across the company as well as the research associated with computer visualization/image analysis and superconducting systems. Mike was named an officer of the General Electric Company in November 2006.

Mike received a bachelor’s degree in Electrical Engineering from Marquette University, Milwaukee, Wisconsin, and he holds numerous U.S. patents in the field of medical imaging and instrumentation.

Kendall O’Brien
Vice President, Group Finance Medical Device and Diagnostics, Group Operating Committee
Johnson & Johnson.

Kendall O’Brien is currently Group Finance Vice President for Johnson & Johnson’s Medical Devices & Diagnostics (MD&D), where she is responsible for overall financial management for MD&D. In this position, she reports directly to J&J Chief Financial Officer Dominic Caruso and is a member of the MD&D Group Operating Committee.

Prior to her promotion to the GOC, Kendall was Vice President and CFO of the North American Pharmaceuticals Group. From 2003 to 2006, Kendall was Vice President of Finance and Strategic Planning for Ethicon. Her career has extended through Consumer, Medical Devices, Health and Wellness, Pharmaceuticals and Corporate.

She has a proven track record in people development and has been an advocate of college recruiting, the Financial Leadership Development Program, mentoring programs and diversity programs at Johnson & Johnson. Kendall is co-chair for the J&J Global Women’s Leadership Initiative. She received the Tribute to Women in Industry award (TWIN) and is an active member of the Healthcare Businesswoman’s Association. and is active in her local community and serves on a township committee.

Kendall earned bachelor’s degrees in both Accounting and Finance at Lehigh University. She is married and the proud mother of two children.